1

#### **Supplementary Appendix**

## 2 Methods

# 3 RT-qPCR and viral RNA level

The total RNA of nasopharyngeal swab, anal swab, and serum specimens were extracted by using a High Pure Viral RNA kit (Roche). Quantitative reverse transcription PCR (RT-qPCR) tests targeting the N and Orf1ab genes of SARS-CoV-2 were performed using commercial kits (Zhongshan Daan Bio-Tech) on the day of sample collection. Duplicate ten-fold serial dilutions  $(5 \times 10^3-10^7 \text{ copies/mL})$  of standard plasmid DNA (Zhongshan Daan Bio-Tech) were prepared to generate a standard curve for analysis of the viral RNA level. Ct values were converted into viral RNA levels (copy/mL) based on the standard curve.

11

### 12 Serum antibody assay

13 The levels of IgM, IgG, and total antibody against the SARS-CoV-2 surface spike protein receptor 14 binding domain in serum specimens were measured by using a chemiluminescence kit (Beijing Wantai 15 Biotech) with a Caris200 automatic chemiluminescence instrument and are represented as cut-off indexes 16 (COIs). The levels of IgA antibody against the SARS-CoV-2 surface spike protein receptor binding 17 domain in serum specimens were tested by using indirect enzyme-linked immunosorbent assay (ELISA) 18 kits (Beijing Hotgen Biotech). The optical density (OD) was read at 450/630 nm (OD<sub>450/630</sub>). The COI 19 and OD<sub>450/630</sub> are expressed as the average of two independent experiments. To define the cut-off for 20 seropositivity, 169 and 128 serum specimens from confirmed patients and healthy persons were used as 21 positive and negative controls, respectively. Specimens with COI values of >1 or OD<sub>450/630</sub> values of >0.3 22 were considered positive.

23

#### 24 Virus neutralisation assay

25 Neutralisation assays were performed using a SARS-CoV-2 virus isolate (20SF014/vero-E6/3, GISAID 26 accession number EPI ISL 403934) in biosafety level 3 (BLS-3) laboratories. Briefly, Vero-E6 cell lines 27 were seeded in 96-well plates at a density of  $1 \times 10^4$ – $2 \times 10^4$  cells in 100 µL of medium. After being heat-28 inactivated at 56 °C for 30 min, serum specimens were serially diluted as follows: 1:4, 1:16, 1:64, 1:256, 29 and 1:1024. SARS-CoV-2 strain 20SF014/vero-E6/3 (titre: 104.67 TCID<sub>50</sub>/50 µL) was co-incubated with 30 or without the serum for 2 h (37 °C, 5% CO<sub>2</sub>). A 100-µL aliquot of this mixture was added to the 31 monolayer of pre-seeded Vero-E6 cells. SARS-CoV-2 virus preparations with titres of 100 TCID<sub>50</sub>/50 32  $\mu$ L, 10 TCID<sub>50</sub>/50  $\mu$ L, 1 TCID<sub>50</sub>/50  $\mu$ L, and 0.1 TCID<sub>50</sub>/50  $\mu$ L were used as positive controls. The plates 33 were kept in an incubator set at 37 °C with 5% CO<sub>2</sub>. When the cells treated with the positive control virus 34 displayed lesions, the cytopathic effect (CPE) of every sample was recorded. The highest titre of the 35 serum at which half of the cells were protected and did not display CPE was considered to be the 36 neutralising antibody titre of the serum. The positive and negative controls used in the antibody assays 37 were also used to define the cut-off for NAb seropositivity. Specimens with titres of  $\geq 1:4$  were 38 considered as positive.

39

#### 40 Virus isolation

41 Briefly, throat swabs specimens were filtered using a 0.22-µm needle filter, and then 100-µl samples

42 were inoculated on Vero cells. After a 1-hour incubation at 37 °C with 5% CO<sub>2</sub>, the cells were washed

43 with phosphate-buffered saline and transferred to cell culture flasks with medium for 72 h at 37 °C with

44 5% CO<sub>2</sub>. The cells were monitored for CPE with light microscopy daily for 10 days. When lesions were

45 observed in 76%–100% of the cells, the flasks were placed in a freezer set at -70 °C and freeze-thawed 46 1–2 times before being harvested to improve the virus titre of the samples. Extraction of nucleic acids 47 from harvested samples was performed with a High Pure Viral RNA Kit in accordance with the 48 manufacturer's instructions (Roche). Extracted RNA was tested for SARS-CoV-2 genes by using an RT-

- 40 manufacturer's instructions (Kocne). Extracted KNA was tested for SARS-CoV-2 genes by using an R1
  49 PCR assay (Zhongshan Daan Bio-Tech).
- 50

### 51 Whole genome sequencing and analysis

52 Reverse transcription was performed by using a SuperScript VILO cDNA Synthesis kit (Thermo Fisher).

53 SARS-CoV-2-specific amplification library construction was performed by using an Ion Ampliseq

Library Kit 2.0 (Thermo Fisher), and sequencing was conducted using an Ion Torrent S5Plus sequencer.

55 Sequenced reads were aligned against a SARS-CoV-2 reference genome (BetaCoV/Wuhan/Wuhan-Hu-

56 1/2019, NCBI accession number MN908947) with CLC Genomic Workbench V9.0 software with 90%

57 identity to evaluate the genome coverage and identify mutations.

58

59

- 60 Figure S1. Temporal distribution of the SARS-CoV-2 viral RNA level in 93 RP-DC patients. Red
- 61 and green colours show viral RNA-positive and -negative patients, respectively. The triangles show viral
- 62 RNA results from testing performed before discharge or during readmission. The rectangles show viral
- 63 RNA results from testing performed during quarantine or follow-up.



64 65

Figure S2. Standard curve based on the RT-qPCR Ct value and viral RNA level of standard

product.



Figure S3. Viral RNA levels in RP-DC patients of different demographic and clinical categories, 

![](_page_3_Figure_6.jpeg)

![](_page_3_Figure_7.jpeg)

![](_page_3_Figure_8.jpeg)

![](_page_3_Figure_9.jpeg)

positive

### 74 Figure S4. Correlation between NAb titres and antibody levels. Red and blue colours indicate RP-

![](_page_4_Figure_1.jpeg)

RC and NRP-RC patients, respectively. Specimens with an NAb titre of <1:4 were assigned a value of 1.